Skip to main content
☩ AI Health Guide
Menu
Last Updated:

Tempus AI Review 2026: The Precision Medicine Platform Reshaping Oncology

Clinician NASDAQ: TEM
Affiliate disclosure: This page contains affiliate links marked with ↗. If you sign up through one of these links, we earn a commission at no extra cost to you. Our rankings and reviews are editorially independent — affiliate relationships do not influence them. Health claims have not been verified by the FDA. Read our methodology →
A

AI Health Apps Editorial Team

Editorial Team, AI Health Guide

Updated

Reviewed against our methodology

About the editorial team  ·  Report an error

Overview: What Is Tempus AI?

Tempus AI is a precision medicine platform that combines large-scale genomic sequencing, AI-driven multimodal analytics, and a generative AI clinical assistant called Tempus One. Founded in 2015 by Eric Lefkofsky in Chicago, Tempus has built one of the largest clinical and molecular datasets in healthcare and partners with more than half of US oncologists and the majority of top 20 global pharmaceutical companies. Tempus is publicly traded on NASDAQ as TEM and projected $1.59B in revenue for 2026.

Tempus is not a single product but a platform: genomic testing panels (xT for tumor DNA, xR for tumor RNA, xF for liquid biopsy), AI diagnostic tools spanning oncology, cardiology and radiology (Tempus Pixel for cardiac MRI, ECG-Low EF for cardiac AI), and Tempus One, the generative AI assistant embedded directly into Epic and other EHRs that lets clinicians query a patient's clinical and molecular history in natural language. The differentiator is the combination — no other vendor offers genomic testing, FDA-cleared diagnostic AI, and embedded generative AI under one roof.

Key Features

  • AI-driven precision medicine platform
  • Genomic sequencing and molecular profiling (xT, xR, xF panels)
  • Tempus One generative AI clinical assistant
  • FDA-cleared ECG AI: Tempus ECG-AF (510(k) K233549, 2024) analyzes 12-lead ECGs for signs of atrial fibrillation or flutter within the next 12 months; not for patient monitoring
  • PRISM2 multimodal pathology foundation model (with Microsoft) — Nature Medicine study (Aug 2026) shows best-in-class diagnostic + prognostic performance, incl. cancer detection and biomarker/prognosis prediction

FDA Status & Clinical Validation

Tempus has multiple FDA 510(k) clearances, which is relatively rare in the AI health space. Its DNA next-generation sequencing test, xT CDx, is not one of them: it is FDA-approved through premarket approval (PMA P210011, April 2023). Tempus xR IVD received clearance in September 2025 for RNA NGS (K241868). Tempus Pixel is a cleared cardiac MRI AI tool (K252539). Tempus ECG-Low EF detects reduced ejection fraction from a standard ECG (K250119), and Tempus ECG-AF looks for signs of atrial fibrillation or flutter within the next 12 months (K233549). Like Aidoc and Viz.ai, Tempus has several FDA-authorized products rather than one.

Beyond FDA, Tempus has extensive peer-reviewed literature and partnerships with the top 20 pharmaceutical companies for clinical trials and real-world evidence generation. The data assets are arguably the company's most valuable property — the combined clinical, molecular, and imaging data on millions of patients is the substrate that the AI tools are trained on.

Pricing

Tempus does not publish standard pricing because it is a multi-product platform with very different revenue models per product. Genomic tests are reimbursed per-exam by Medicare and commercial payers, with the Medicare NTAP rate around $601-$700 per exam in 2026 depending on the specific assay. Platform licensing for health systems is custom and negotiated. Pharmaceutical data partnerships are bespoke. For an oncology practice evaluating Tempus, the practical question is whether your payer mix will cover the test reimbursement — not whether you can budget a flat monthly fee.

Tempus One: The Generative AI Layer

Tempus One is the generative AI clinical assistant that ships embedded into Epic (via the Genomics module) and other major EHRs. It lets clinicians query patient data in natural language: "Show me this patient's actionable mutations and matched clinical trials." It is purpose-built for oncology workflow and grounded in Tempus's underlying clinical and molecular dataset. This is where Tempus differs structurally from competitors like Foundation Medicine that offer testing without a generative AI layer.

Pros & Cons

Strengths

  • ✓ Multiple FDA 510(k) clearances across genomics and cardiac AI
  • ✓ Largest multimodal clinical and molecular dataset in oncology
  • ✓ Tempus One generative AI embedded in Epic Genomics
  • ✓ Partners with majority of top 20 global pharma companies
  • ✓ Publicly traded with regulatory transparency

Weaknesses

  • ✗ Complex product portfolio can be confusing to buyers
  • ✗ Primarily oncology-focused — less relevant for general practice
  • ✗ Enterprise procurement complexity
  • ✗ Not yet profitable (projecting first positive EBITDA in 2026)
  • ✗ Expensive genomic testing vs simpler AI tools

Who Should Evaluate Tempus?

Tempus is built for oncology practices, academic medical centers running molecular tumor boards, cardiology departments evaluating Tempus Pixel and ECG-Low EF, and pharma companies needing real-world data partnerships. It is also relevant for any health system that wants generative AI embedded in oncology Epic workflows. It is not appropriate for general primary care, small practices without oncology volume, or organizations looking for a single ambient AI scribe (see Abridge or Freed instead).

Verdict

Tempus AI is the most ambitious AI platform in oncology, with an FDA premarket approval for xT CDx (April 2023) and FDA 510(k) clearances including Tempus ECG-AF (June 2024). The combination of FDA-cleared diagnostics, large-scale genomic data, and embedded generative AI is genuinely differentiated. For oncology programs evaluating precision medicine vendors, Tempus belongs on the short list alongside Foundation Medicine, Caris, and Guardant. For any other use case, the platform is overscoped. We recommend Tempus for oncology and cardiac AI buyers and direct other clinical workflows to category-specific tools.

Frequently asked questions

What does Tempus AI actually do?
Tempus AI is a multi-modal precision-medicine platform that combines genomic sequencing, imaging analysis, and clinical-data integration with AI / generative-AI layers on top. Primary use cases are oncology (molecular profiling, treatment selection), cardiology, and neuropsychiatry. Tempus is more platform than single-product — most customers use a subset of the product surface relevant to their specialty.
Is Tempus AI FDA-cleared?
Yes — Tempus has multiple FDA-cleared diagnostic devices including FDA-cleared genomic profiling and FDA-cleared cardiac imaging tools. The list of cleared devices grows; check the FDA website for the current set.
How does Tempus get reimbursed?
For oncology genomic profiling (Tempus xT and similar), Medicare reimbursement is well-established with NTAP (New Technology Add-on Payment) coverage at approximately $601–$700 per exam for 2026. Other Tempus services have more fragmented reimbursement.
Tempus vs Foundation Medicine vs Caris — which is better for oncology?
All three are credible vendors in oncology genomic profiling. Foundation Medicine has the longest track record and strongest clinician familiarity. Caris has the largest commercial volume. Tempus differentiates on the AI/data-platform layer plus cardiology and neuropsychiatry breadth. For pure oncology genomic profiling, all three are reasonable; the decision often comes down to existing clinical relationships and lab integration.
Is Tempus appropriate for non-oncology use?
Tempus has cardiology AI products and neuropsychiatry initiatives, but the core platform is built around oncology data and workflows. For non-oncology AI imaging, dedicated tools (Aidoc, Viz.ai for radiology; PathAI for pathology) are typically better fit. Tempus is overscoped for non-oncology workflows.
For Clinicians: Freed Try Freed ↗